AFAP1 and metastatic malignant neoplasm in the lymph nodes: The results indicated that patients with cancer with high expression of AFAP1-AS1 had a higher risk of lymph node metastasis and distant metastasis, and the OS rate, PFS rate, and recurrence free survival (RFS) rate of patients with high expression of AFAP1-AS1 were lower than those with low expression.